## **Chronic Q Fever Enhanced Surveillance**

Thank you for consulting with CDC; please complete the information below to help us learn more about the clinical manifestations of chronic Q fever in the United States.

Form Approved OMB No. 0920-XXXX Exp. Date: XX/XX/20XX

The following enhanced chronic Q fever clinical surveillance tool was developed to gather more detailed and specific clinical data on chronic Q fever to better understand its presentation, management, and long-term outcomes. This information will allow for better characterization of chronic Q fever in the United States.

Your participation in this survey is strictly voluntary and you may stop at any time. All information collected will remain anonymous; we will not collect any personally identifiable information, such as your patient's name or contact information. There are no negative consequences to you should you decline to participate or not complete the survey in its entirety. You may continue to consult with CDC's Rickettsial Zoonoses Branch regardless of your participation in enhanced surveillance.

This survey should take you approximately 20 minutes to complete.

If you have any questions or concerns about completing this survey, please contact: 404-639-1075 or rzbepidiag@cdc.gov.

The Rickettsial Zoonoses Branch thanks you for your time and involvement.

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-XXXX

Demographics	
When was this patient first diagnosed with chronic Q fever?	
	(YYYY; If unknown, leave blank.)
Patient's age at first diagnosis	
	(in years)
Sex of patient	

**REDCap** 

State of Residence	○ Alabama
	○ Alaska
	Arizona
	○ Arkansas
	○ California
	○ Colorado
	○ Connecticut
	O Delaware
	O District of Columbia
	Florida
	○ Georgia
	Hawaii
	O Idaho
	Illinois
	○ Indiana
	Olowa
	○ Kansas
	○ Kentucky
	○ Louisiana
	○ Maine
	<ul><li>Michigan</li></ul>
	Minnesota
	Mississippi
	Missouri
	○ Montana
	○ Nebraska
	○ Nevada
	New Hampshire
	New Jersey
	New Mexico
	New York
	North Carolina
	○ North Dakota
	Ohio
	Oklahoma
	○ Oregon
	○ Pennsylvania
	○ Rhode Island
	○ South Carolina
	○ South Dakota
	○ Tennessee
	○ Texas
	O Utah
	○ Vermont
	Washington
	○ West Virginia
	Wisconsin
	Wyoming
	Puerto Rico
	U.S. Virgin Islands
	Guam
	American Samoa
	Northern Mariana Islands

10/02/2019 11:39am

Page 3 of 16

Race	<ul> <li>☐ American Indian or Alaska Native</li> <li>☐ Asian</li> <li>☐ Black or African American</li> <li>☐ Native Hawaiian or Other Pacific Islander</li> <li>☐ White</li> <li>☐ Unknown</li> <li>(select all that apply)</li> </ul>
Ethnicity	<ul><li></li></ul>

**REDCap** 

Acute Q fever history	
Was this patient previously diagnosed with acute Q fever?	
Is the date of acute Q fever diagnosis known?	○ Yes ○ No
Year of acute Q fever diagnosis.	
	(YYYY)
How was the initial diagnosis made?	☐ PCR ☐ Paired Serology ☐ Single serology ☐ Other ☐ Unknown (Select all that apply.)
If other diagnostic used, specify.	
Was the patient treated for acute Q fever?	
What medication(s) was/were used?	<ul> <li>□ Doxycycline</li> <li>□ Trimethoprim/sulfamethoxazole</li> <li>□ Other</li> <li>□ Unknown</li> <li>(Select all that apply.)</li> </ul>
Pleas specify what other antibiotics were prescribed?	
	(Use the common name for the drug or chemical, no trade name.)
How long was the patient on the medication for treatment of acute Q fever?	(Number of days. )
Was this patient pregnant at the time of acute Q fever diagnosis?	○ Yes ○ No ○ Unknown
In which trimester did the symptoms begin?	<ul><li> 1st (weeks 1-12)</li><li> 2nd (weeks 13-28)</li><li> 3rd (weeks 29-42)</li><li> Unknown</li></ul>
Was the patient treated during pregnancy?	○ Yes    ○ No    ○ Unknown
At what week gestation did treatment begin?	
	(Week number)
Is the patient still receiving treatment?	○ Yes ○ No ○ Unknown

How long was the patient on medication before treatment was discontinued?	(Number of weeks.)
What antibiotics are/were used?	<ul><li>☐ Trimethoprim/sulfamethoxazole</li><li>☐ Other</li><li>☐ Unknown</li></ul>
If other antibiotic use, specify.	
	(Use the common name for the drug or chemical, not trade name.)
Did this patient develop placentitis?	○ Yes    ○ No    ○ Unknown
Did this patient develop any of the following complications of pregnancy?	☐ Intrauterine growth restriction (IUGR) ☐ Stillbirth ☐ Miscarriage ☐ Premature delivery ☐ Other ☐ No complications ☐ Unknown (Select all that apply.)
If other complication of pregnancy, please specify.	
	<del></del>
Where any of the following newborn complications present?	☐ Malformations ☐ Hyperbilirubinemia ☐ Kernicterus ☐ Other ☐ No complications ☐ Unknown (Select all that apply.)
If malformations, please specify types.	
What other newborn complications were present?	
What was the gestational age at birth?	
	(Weeks)
What was the weight at birth?	
	(in pounds)

KISK Factors	
Did this patient have a history of any of the following cardiovascular conditions?	No history of cardiovascular conditions   Rheumatic heart disease   Aortic valve stenosis   Aortic valve prolapse   Aortic valve regurgitation   Mitral valve stenosis   Mitral valve prolapse   Mitral valve regurgitation   Pulmonic valve stenosis   Pulmonic valve prolapse   Pulmonic valve prolapse   Tricuspid valve regurgitation   Tricuspid valve regurgitation   Tricuspid valve regurgitation   Tricuspid valve regurgitation   Prosthetic valve   Aneurysm   Vascular graft/stent   Atrial septal defect   Patent ductus arteriosus   Ventricular septal defect   Tetralogy of Fallot   Other congenital heart defect   Other heart valve problem   Unknown   (Check all that apply.)
Which valve was replaced?	☐ Aortic ☐ Mitral ☐ Pulmonic ☐ Tricuspid ☐ Unknown (Select all that apply)
Year of most recent replacement.	
	(YYYY)
What type of valve replacement did the patient receive?	<ul> <li>Manufactured mechanical valve</li> <li>Human donor valve</li> <li>Bioprosthetic - bovine</li> <li>Bioprosthetic - porcine</li> <li>Other</li> <li>Unknown</li> </ul>
Please specify other valve replacement received.	
History of >1 valve replacement?	○ Yes    ○ No    ○ Unknown
Please specify other congenital heart defect.	
Please specify other heart valve problem.	

Clinical Findings	
What clinical signs and symptoms has the patient exhibited?	☐ Relapsing fever ☐ Chills ☐ Weight loss ☐ Night sweats ☐ Fatigue ☐ Shortness of breath ☐ Hepatosplenomegaly ☐ Other ☐ Unknown (Select all that apply.)
Please specify what other clinical signs and symptoms the patient has exhibited.	

Endocarditis	
Did this patient have culture negative endocarditis?	
Please specify affected valve(s)	☐ Aortic valve ☐ Mitral valve ☐ Pulmonary valve ☐ Tricuspid valve ☐ Unknown (Select all that apply.)
What imaging technologies were used to diagnose endocarditis?	☐ Transthoracic echocardiogram (TTE) ☐ Transesophageal echocardiogram (TEE) ☐ PET CT Scan ☐ CT Scan ☐ MRI ☐ Other ☐ Unknown (Select all that apply.)
Please specify what other imaging was/were used to diagnose endocarditis.	
Was the infected valve removed?	○ Yes  ○ No  ○ Unknown
Please specify the year of valve removal.	
	(YYYY)
Was the valve tested for the presence of Coxiella burnetii?	
Which testing method was used on the valve sample?	☐ PCR ☐ IHC ☐ Culture ☐ Unknown (Select all that apply.)
What were the diagnostic results?	<ul><li>Positive</li><li>Negative/undetermined</li><li>Unknown</li></ul>

projectredcap.org

10/02/2019 11:39am

vascular intection	
Did this patient have a vascular infection (i.e. infection of vascular graft, stent, or aneurysm) caused by Coxiella burnetii?	
Please specify which type of vascular infection.	☐ Vascular graft ☐ Stent ☐ Aneurysm ☐ Other ☐ Unknown
Please specify what other type of vascular infection was present.	
Please specify location of infection.	☐ Abdominal aorta ☐ Thoracic aorta ☐ Other ☐ Unknown
Please specify the other location of infection.	
What year was the now infected graft/stent originally placed?	(YYYY)
Was infected graft/stent removed or aneurysm repaired?	○ Yes    ○ No    ○ Unknown
Please specify the year of removal or repair surgery.	(YYYY)
Was the vascular infection tested for presence of Coxiella burnetii?	
Which testing method was used to on the vascular infection sample?	☐ PCR ☐ IHC ☐ Culture ☐ Unknown (Select all that apply.)
What were the diagnostic results?	<ul><li>Positive</li><li>Negative/undetermined</li><li>Unknown</li></ul>

10/02/2019 11:39am

Osteoarticular intection	
Did this patient have an osteoarticular infection (e.g. osteomyelitis or spondylodiscitis) caused by Coxiella burnetii?	
Please specify location of osteoarticular infection.	
Was this a native joint?	<ul><li>Yes</li><li>No</li><li>Unknown</li><li>Not applicable</li></ul>
Was surgical debridement of the diseased tissue and bone performed?	
Specify the year of most recent debridement.	
	(YYYY)
During the debridement, was any tissue tested for presence of Coxiella burnetii?	
Which testing method was used on the debrided tissue?	☐ PCR ☐ IHC ☐ Culture ☐ Unknown (Select all that apply.)
What were the diagnostic results?	<ul><li>○ Positive</li><li>○ Negative/undetermined</li><li>○ Unknown</li></ul>

Granulomatous nepatitis	
Did this patient have evidence of granulomatous hepatitis?	○ Yes    ○ No    ○ Unknown
Which liver function tests were elevated?	☐ Alk Phos ☐ ALT ☐ AST ☐ LDH ☐ Bilirubin ☐ Albumin ☐ GGT (Select all that apply. )
Which imaging techologies were used to diagnose hepatitis?	☐ Ultrasound ☐ MRI ☐ MRE (elastography) ☐ CT ☐ Other ☐ No imaging performed (Select all that apply)
What other imaging technology was used to diagnose hepatitis?	
Was a liver biopsy performed?	○ Yes    ○ No    ○ Unknown
What year was the liver biopsy performed?	
	(YYYY)
Was the biopsy tested for presence of Coxiella burnetii?	
Which testing method was used on the liver biopsy?	☐ PCR ☐ IHC ☐ Culture ☐ Unknown (Select all that apply.)
What were the diagnostic results?	<ul><li>○ Positive</li><li>○ Negative/undetermined</li><li>○ Unknown</li></ul>

Lymphadenopathy	
Did this patient develop lymphadenopathy?	○ Yes ○ No ○ Unknown
Please specify location of lymphadenopathy(s)	☐ Cervical ☐ Supraclavicular ☐ Axillary ☐ Perihilar ☐ Mediastinal ☐ Mesenteric ☐ Inguinal ☐ Popliteal ☐ Other (Select all that apply.)
If other location of lymphadenopathy, please specify.	
Was a lymph node biopsy performed?	○ Yes  ○ No  ○ Unknown
Was the biopsy tested for presence of Coxiella burnetii?	
Which testing method was used on the lymph node biopsy?	☐ PCR ☐ IHC ☐ Culture ☐ Unknown (Select all that apply.)
What were the diagnostic results?	<ul><li>○ Positive</li><li>○ Negative/Undetermined</li><li>○ Unknown</li></ul>

Additional complications	
Did this patient develop any of the following complications?	☐ Psoas abscess ☐ Cardiac abscess ☐ Empyema or other pulmonary abscess ☐ Other abscess ☐ Ruptured aneurism ☐ None of the above ☐ Unknown (Select all that apply.)
Please specify the location of the other abscess.	
Was medical intervention performed?	○ Yes    ○ No    ○ Unknown
What interventions were performed?	☐ Incision and drainage ☐ Marsupialization ☐ Indwelling drain ☐ Other ☐ Unknown (Select all that apply.)
Please specify what other intervention was performed.	
What year was the intervention performed?	
	(YYYY)
Was any material from the abscess or rupture tested for Coxiella burnetii?	
What was the method used to test material from the abscess?	☐ PCR ☐ IHC ☐ Culture ☐ Unknown (Select all that apply.)
What was the result of testing?	<ul><li>Positive</li><li>Negative/undetermined</li><li>Unknown</li></ul>
Did this patient develop an embolic stroke or infarct?	○ Yes    ○ No    ○ Unknown
Please specify the location of the embolic stroke or infarct.	
Was this patient admitted to the hospital for chronic Q fever?	○ Yes ○ No ○ Unknown
Please provide the number of times the patient was hospitalized at least overnight for complications of chronic Q fever since the initial chronic Q diagnosis	(# of hospitalizations)

Antibiotics	
Which antibiotics did the patient receive?	☐ Doxycycline ☐ Hydroxychloroquine ☐ Other ☐ None ☐ Unknown (Select all that apply)
Please specify what other antibiotics is/was the patient on.	(Use the common name for the drug or chemical, not trade name.)
How many months has the patient been on antibiotic therapy?	(Number of Months)
Has the patient completed antibiotic therapy?	○ Yes ○ No ○ Unknown
Did the patient develop any of the following side effects or complications from antibiotic therapy?	<ul> <li>Nausea/other GI upset</li> <li>Retinal damage</li> <li>QT prolongation</li> <li>Photosensitivity</li> <li>Irreversible skin pigmentation</li> <li>Other</li> <li>None</li> <li>Unknown</li> <li>(Select all that apply.)</li> </ul>
Please specify what other side effects or complications the patient developed from antibiotic therapy.	
Was the patient taken off any antibiotic during treatment due to side effects?	○ Yes    ○ No    ○ Unknown
Which medication(s) were stopped?	<ul><li>□ Doxycycline</li><li>□ Hydroxychloroquine</li><li>□ Other</li><li>(Select all that apply)</li></ul>
What other antibiotic was stopped?	
	(Use the common name for the drug or chemical, not trade name.)
What were the side effects that led to the medication being discontinued?	<ul> <li>Nausea/other GI upset</li> <li>Retinal damage</li> <li>QT prolongation</li> <li>Photosensitivity</li> <li>Irreversible skin pigmentation</li> <li>Fatigue</li> <li>Other</li> <li>(Select all that apply.)</li> </ul>
Please specify other side effects that led to medication to medication being discontinued.	

Serology	
On average, how frequently are/were Q fever serologies collected from the patient?	(Average months (#))
What was the Phase 1 IgG serology titer value at the initial chronic Q diagnosis?	(Record the only reciprocal titer (e.g. 64, 128, 256))
What was the Phase 2 IgG serology titer value at the initial chronic Q diagnosis?	(Record the only reciprocal titer (e.g. 64, 128, 256))
What was the most recent Phase 1 IgG titer value recorded?	(Record the only reciprocal titer (e.g. 64, 128, 256))
What was the most recent Phase 2 IgG titer value recorded?	(Record the only reciprocal titer (e.g. 64, 128, 256))
How many weeks ago was the most recent serology collected?	(Number of weeks)
At any point during treatment, has a four-fold reduction in Phase 1 titers been observed?	○ Yes ○ No ○ Unknown



Page 16 of 16

Outcome	
Did the patient die from complications of this illness?	
What was the cause of death per death certificate?	

**REDCap**